The inhibition of the CXCR4‐CXCL12 pathway has been shown to enhance T‐cell access to the TME and increase tumor sensitivity to anti‐PD‐L1 therapy.[48, 49, 50] Ccn1‐deficient KPC cells exhibit decreased chemokine expression and increased immune cell infiltration. This evidence concerns the gene CXCR4 and neoplasm.